as of 12-12-2025 3:44pm EST
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 433.8M | IPO Year: | 2021 |
| Target Price: | $5.88 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.37 - $7.30 | Next Earning Date: | 11-05-2025 |
| Revenue: | $196,828,000 | Revenue Growth: | -2.18% |
| Revenue Growth (this year): | -0.1% | Revenue Growth (next year): | 5.62% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how CTKB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CTKB Cytek Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.